The price of Cibinqo varies based on factors like dosage, insurance coverage, and pharmacy. As of late 2023 and early 2024, without insurance, a 30-day supply of Cibinqo (abrocitinib) could range from approximately $2,500 to over $4,000 for both the 100 mg and 50 mg doses [1].
How can I get financial assistance for Cibinqo?
Patients may be eligible for financial assistance programs offered by the manufacturer, Pfizer. The Cibinqo Savings Card program, for instance, can reduce out-of-pocket costs for eligible commercially insured patients. For those without insurance, Pfizer also offers a Patient Assistance Program that provides free medication to qualifying individuals based on income [1].
What is Cibinqo and what is it used for?
Cibinqo (abrocitinib) is a Janus kinase 1 (JAK1) inhibitor prescription medication used to treat moderate to severe atopic dermatitis (eczema) in adults and children 12 years and older whose condition has not responded to other treatments [1].
How does Cibinqo work?
Cibinqo works by blocking the activity of JAK1, a protein involved in the body's inflammatory pathways. By inhibiting JAK1, Cibinqo helps to reduce the itching and skin inflammation associated with atopic dermatitis [1].
What are the potential side effects of Cibinqo?
Common side effects of Cibinqo include upper respiratory tract infections, nausea, headache, and increased blood creatine phosphokinase. More serious risks can include serious infections, blood clots, cardiovascular events, cancer, and changes in laboratory test results. Patients should discuss their complete medical history and any concerns with their doctor before starting treatment [1].
When does the patent for Cibinqo expire?
Information regarding specific patent expiry dates for Cibinqo can be found on specialized patent tracking websites. For instance, DrugPatentWatch.com provides detailed patent information for pharmaceuticals, including expiry timelines [2].
Who are Cibinqo's main competitors?
The market for atopic dermatitis treatments includes other JAK inhibitors such as Upadacitinib (Rinvoq) and Baricitinib (Olumiant). Biologics like Dupilumab (Dupixent) are also significant competitors [3].